## **ABSTRACT**

The present invention relates to CCR5 receptor antagonists of formulae (1a) or (1b):

5

$$R^5$$
 $R^4$ 
 $(CH_2)n$ 
 $R^4$ 
 $(CH_2)n^*$ 
 $(1a)$ 
 $R^2$ 
 $R^3$ 
 $(CH_2)n^*$ 
 $(1b)$ 

enantiomers, diastereomers, salts and solvates thereof wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ , and  $R^7$  are as defined herein. The invention further includes a method of CCR5-mediated disorders employing such compounds.